EUVIMEDEUVIMED entdecken
Crossref

Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus

Long-Wang Lin, Yu-Xia Nian, Xin Lin, Kun Ke, Wei-Zhu Yang, Jun-Qing Lin, Ning Huang

CardioVascular and Interventional Radiology · 10.12.2024 · 48 (3) · 314-326

DOI: 10.1007/s00270-024-03919-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift CardioVascular and Interventional Radiology, online erschienen am 10.12.2024. Verfasst von Long-Wang Lin und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, 350001, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Phenylurea Compounds, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Medical Innovation Project of Fujian Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The aim of this study was to assess the safety and effectiveness of transarterial chemoembolization (TACE) plus lenvatinib with a programmed death-1 (PD-1) inhibitor compared with TACE plus lenvatinib and TACE alone for hepatocellular carcinoma (HCC) with the hepatic vein and/or inferior vena cava tumor thrombus (HVTT and IVCTT). METHODS: Data on HCC accompanied by HVTT and IVCTT from June 2015 to August 2022 were analyzed in this single-center retrospective study. Drug-eluting bead TACE (DEB-TACE) or conventional TACE (cTACE) was used. The primary study outcomes were overall survival (OS) and progression-free survival (PFS). Univariate and multivariate Cox analyses were performed to determine the predictive factors for OS and PFS. A subgroup analysis was conducted. RESULTS: Overall, 214 patients were enrolled. Among them, 60 received triple therapy consisting of TACE, lenvatinib, and PD-1 inhibitors (TACE + L + P), 72 received dual therapy consisting of TACE and lenvatinib (TACE + L), and 82 received TACE alone. The TACE + L + P group (16.2; 95% confidence interval [CI]: 12.8-19.5 months) had a significantly longer median OS compared with the TACE + L group (11.2; 95% CI: 10.0-12.3 months) (P = 0.001) and the TACE group (8.3; 95% CI: 7.7-8.5 months) (P < 0.001); the TACE + L + P group (12.3; 95% CI: 10.9-13.7 months) had a significantly longer median PFS compared with the TACE + L group (8.5; 95% CI: 7.7-9.2 months) (P < 0.001) and the TACE group (6.2; 95% CI: 5.8 ~ 6.3 months) (P < 0.001). Multivariate Cox analysis demonstrated that treatment strategy was a significant factor for OS and PFS. Skin rash was more common in the triple therapy group and might be attributed to PD-1 ligand inhibitor therapy (33.33% vs. 16.66%, P = 0.026). CONCLUSIONS: Triple therapy consisting of TACE plus lenvatinib with a PD-1 inhibitor showed promising efficacy for advanced HCC patients with HVTT and IVCTT, with manageable safety profiles.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsPhenylurea CompoundsChemoembolization, TherapeuticQuinolinesVenous ThrombosisImmune Checkpoint InhibitorsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedVena Cava, InferiorHepatic VeinsTreatment OutcomeAntineoplastic AgentsCombined Modality TherapyAdult

Stichwörter der Autor:innen

Hepatocellular carcinomaInferior vena cava tumor thrombusLenvatinibProgrammed death-1 inhibitorTransarterial chemoembolization

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesAntineoplastic AgentsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
  • Department of Prevention and Healthcare, Fujian Medical University Union Hospital, Fuzhou, 350001, China.
  • Department of Interventional Radiology, Fujian Medical University Union Hospital, Fuzhou, 350001, China. hnjrun@163.com.

Förderung

  • Medical Innovation Project of Fujian Province

Zitieren

APA

Lin, L. W., Nian, Y. X., Lin, X., Ke, K., Yang, W. Z., Lin, J. Q., & Huang, N. (2024). Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus. CardioVascular and Interventional Radiology, 48(3), 314-326. https://doi.org/10.1007/s00270-024-03919-2

Vancouver

Lin LW, Nian YX, Lin X, Ke K, Yang WZ, Lin JQ, et al. Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus. CardioVascular and Interventional Radiology. 2024;48(3):314-326. doi:10.1007/s00270-024-03919-2

BibTeX
@article{Lin2024,
  author = {Lin, Long-Wang and Nian, Yu-Xia and Lin, Xin and Ke, Kun and Yang, Wei-Zhu and Lin, Jun-Qing and Huang, Ning},
  title = {Efficacy and Safety of Transarterial Chemoembolization Combined with Lenvatinib Plus Programmed Death-1 Inhibitor for Hepatocellular Carcinoma with the Hepatic Vein and/or Inferior Vena Cava Tumor Thrombus},
  journal = {CardioVascular and Interventional Radiology},
  year = {2024},
  volume = {48},
  number = {3},
  pages = {314--326},
  doi = {10.1007/s00270-024-03919-2}
}
Kostenlos starten →